Ragosa Mark
CHIEF FINANCIAL OFFICER
Ragosa Mark has filed 11 SEC Form 4 filings (42 transaction rows) across 1 company, with disclosures dating back to 2025. 8 of those filings fall inside the rolling window. Most recent filing: Nov 3, 2026.
On the most recent filing, Ragosa Mark is listed as CHIEF FINANCIAL OFFICER at Kiniksa Pharmaceuticals International, plc. Inside the rolling window, Ragosa Mark reported no open-market purchases and 5 open-market sales totaling $8.1M in KNSA. The largest disclosed transaction in the window is a sale of 36,783 KNSA shares on Nov 2, 2026, worth $3.4M.
Companies traded
Other insiders at KNSA
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$8.1M
reported sales (SEC code S)
Companies
1
in the rolling window
Earlier trades
Open-market purchases and sales filed before the rolling 365-day window, kept from the original Form 4 filings.
Frequently asked questions
How many SEC Form 4 filings has Ragosa Mark made?
Ragosa Mark has filed 11 SEC Form 4 filings (42 transaction rows) across 1 company since 2025.
Which companies does Ragosa Mark trade?
Ragosa Mark has filed SEC Form 4 disclosures for 1 company, including KNSA.
When was Ragosa Mark's most recent SEC Form 4 filing?
Ragosa Mark's most recent SEC Form 4 filing on Tracefour is dated Nov 3, 2026.
What is Ragosa Mark's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Ragosa Mark is listed as CHIEF FINANCIAL OFFICER.
What is Ragosa Mark's total buy and sell value in the current window?
Inside the rolling retention window, Ragosa Mark bought $0 and sold $8.1M based on SEC Form 4 filings.
What was Ragosa Mark's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 36,783 KNSA shares on 2026-11-02, worth $3.4M, per SEC Form 4 filings.